Appealing Dupixent Pediatric Coverage Denials

Dupixent is FDA-approved for children as young as 6 months for eczema and age 6+ for asthma. If your child's coverage was denied, this guide covers pediatric-specific appeal strategies.

FDA-Approved Pediatric Indications

  • Atopic Dermatitis: Ages 6 months+ (moderate-to-severe)
  • Asthma: Ages 6+ (moderate-to-severe eosinophilic)
  • EoE: Ages 1+ (eosinophilic esophagitis, ≥1 kg)

Common Denial Reasons for Children

  1. Age not meeting plan criteria (may differ from FDA label)
  2. Insufficient documentation of topical steroid failure
  3. SCORAD/EASI score not high enough
  4. Missing specialist evaluation

Building a Strong Pediatric Appeal

Document Severity

  • SCORAD or EASI scoring by dermatologist
  • Photographs showing extent and severity
  • Sleep disruption documentation
  • School absence records
  • Quality of life impact (CDLQI scores)

Treatment History

  • All topical steroids/calcineurin inhibitors tried with dates
  • Phototherapy if attempted
  • Systemic immunosuppressants tried (if age-appropriate)

Specialist Support

  • Pediatric dermatologist or allergist letter
  • Reference AAD guidelines for pediatric atopic dermatitis
  • Cite FDA approval and clinical trial data (LIBERTY AD PEDS)

Need Help Writing Your Appeal?

Our AI-powered tool analyzes your denial letter and generates a personalized appeal in minutes. Upload your denial and get started for free.

Start Your Free Appeal

Frequently Asked Questions

Is Dupixent safe for children?

Dupixent has been studied in clinical trials for children as young as 6 months for eczema. The FDA approval is based on safety and efficacy data from these trials. Your pediatric specialist can address specific safety questions for your child.

Related Resources